Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia

Authors :: Jorge J, Castillo
Edward N, Libby
Stephen M, Ansell
M Lia, Palomba
Kirsten, Meid
Catherine A, Flynn
Carly, Leventoff
Christopher B, Hergott
Tomasz, Sewastianik
Elizabeth A, Morgan
Ruben, Carrasco
Jonathan R, Fromm
Guang, Yang
Zachary, Hunter
Steven P, Treon
Source :: Blood Adv
Publication Year :: 2020
Abstract: Daratumumab was associated with an overall response of 23% and a median PFS of 2 months in previously treated patients with WM. The 2 patients who attained a partial response to daratumumab exhibited higher baseline CD38 median fluorescent intensity in plasma cells.

Subjects :: Receptors, CXCR4
Antibodies, Monoclonal
Humans
Waldenstrom Macroglobulinemia
Stimulus Report

Tools